Engine Biosciences, a Singapore-based biotechnology firm, has secured a $5 million investment from GV, Alphabet’s venture capital arm. This funding highlights a growing investor confidence in leveraging artificial intelligence for oncology drug discovery. The company, which operates between Singapore and Silicon Valley, aims to accelerate the development of precision medicine for cancer patients.
Strengthening Investor Confidence
The investment from GV follows another significant capital injection from Pfizer Ventures, which recently became Engine's second-largest shareholder. This move marked Pfizer's first startup investment in the Southeast Asian region. These endorsements from major corporate venture arms underscore the perceived potential of Engine's technology and strategic direction.
Earlier this year, the company also raised $13.6 million from its existing network of investors. This group includes prominent backers such as Polaris Partners, ClavystBio, SEEDS Capital, and Coronet Ventures. This consistent support from its current investors demonstrates a strong belief in the company's long-term vision and progress.
Innovating with a Hybrid Platform
Engine Biosciences differentiates itself through a unique approach that combines machine learning with high-throughput experimental biology. Its proprietary NetMAPPR platform is designed to map complex biological networks and identify genetic interactions that drive cancer. This method allows for the discovery of novel drug targets and patient-selection biomarkers with greater precision.
Unlike purely computational models, Engine’s system is built to experimentally validate its AI-driven predictions before advancing them. This crucial step is intended to increase the probability of success as potential drug targets move into the development pipeline. The company reported in 2023 that this process had already uncovered over 30 previously unidentified precision medicine opportunities.
Advancing Towards Clinical Application
The company is actively translating its discoveries into tangible therapeutic programs. In a key partnership, Engine is collaborating with Singapore’s Experimental Drug Development Centre (EDDC) to co-develop precision cancer therapies. This collaboration leverages national infrastructure to bridge the gap between discovery and clinical readiness.
The first program under this partnership focuses on ENB-871, a drug target and biomarker pair identified by the NetMAPPR platform. Engine and EDDC are developing small-molecule degraders against this target for genetically defined subsets of several cancers. The goal is to demonstrate their effectiveness in preclinical models, paving the way for future human trials.
Riding a Wave of Sector Investment
This funding arrives amidst a significant resurgence in venture capital for AI-powered drug discovery. The sector has seen investment grow substantially in recent years, reflecting a broader conviction that AI can revolutionize the pharmaceutical industry. This trend is creating a fertile ground for innovative companies like Engine to secure necessary growth capital.
The scale of recent investments in the field is notable, with companies like Google DeepMind's Isomorphic Labs raising substantial capital. Furthermore, major venture firms such as Andreessen Horowitz and Dimension Capital are allocating hundreds of millions towards the intersection of biology and computing. GV's investment in Engine aligns with its broader strategy of backing pioneering AI healthcare companies.
The latest $5 million from GV provides Engine Biosciences with additional resources to advance its promising pipeline and validate its hybrid discovery platform. While the ultimate test remains the successful translation of AI-generated insights into effective clinical therapies, this investment strengthens the company's position. It places the Singaporean biotech at the forefront of a global effort to reshape the economics of medicine through artificial intelligence.
Source: Deal Street Asia